Mankind Pharma (MANKIND) Fundamentals 2026 — P/E 54.6x, Revenue Analysis | SniperIQ
Mankind Pharma (MANKIND) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹1.05 Lakh Crore, trading at ₹2544.05 on the BSE. This SniperIQ fundamentals page covers Mankind Pharma's valuation (P/E 54.6x, P/B 6.4x), profitability (net margin 13.4%), revenue (₹14,278 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Mankind Pharma's market cap?
Mankind Pharma (MANKIND) has a market capitalization of approximately ₹1.05 Lakh Crore, trading at ₹2544.05 on the BSE. Market cap moves with the live share price.
What is Mankind Pharma's P/E ratio?
Mankind Pharma's trailing twelve-month P/E ratio is 54.6x, with a price-to-book (P/B) of 6.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Mankind Pharma?
Mankind Pharma runs a net profit margin of 13.4%, a gross margin of 57.5%, and an operating margin of 19.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Mankind Pharma generate?
Mankind Pharma reported revenue of ₹14,278 Crore for fiscal year 2026, with net income of ₹1,913 Crore and earnings per share (EPS) of 46.35. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Mankind Pharma pay a dividend?
Mankind Pharma offers a trailing dividend yield of about 0.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Mankind Pharma financially healthy?
Mankind Pharma carries a debt-to-equity ratio of 0.39x and a current ratio of 1.07x, with a market beta of 0.45. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Mankind Pharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Mankind Pharma (MANKIND) the key facts are: market cap ₹1.05 Lakh Crore, P/E 54.6x, revenue ₹14,278 Crore, 52-week range 1909.9-2688.45. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Mankind Pharma's full fundamentals live
Get Mankind Pharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.